Lesson plan

Omberacetam

Omberacetam, also known as N-phenylacetyl- -prolylglycine ethyl ester, is promoted as a nootropic and is a prodrug of cyclic glycine-proline. Other names include the brand name Noopept ( ), developmental code GVS-111. Its synthesis was first reported in 1996. It is orally available. As of 2017, its metabolism and elimination half-life in humans were not well understood. It has been evaluated for neuroprotective effects in treating brain injuries and stroke.

Back to article

Article summary

Omberacetam, also known as N-phenylacetyl- -prolylglycine ethyl ester, is promoted as a nootropic and is a prodrug of cyclic glycine-proline. Other names include the brand name Noopept ( ), developmental code GVS-111. Its synthesis was first reported in 1996. It is orally available. As of 2017, its metabolism and elimination half-life in humans were not well understood. It has been evaluated for neuroprotective effects in treating brain injuries and stroke.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.